deltatrials
Completed PHASE3 NCT00092430

Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016)

A Comparison of the Safety, Tolerability, and Immunogenicity of a Refrigerator-Stable Measles, Mumps, Rubella, and Varicella Combination Vaccine V221 (Refrigerated) Versus V221 (Frozen) in Healthy Children

Sponsor: Merck Sharp & Dohme LLC

Conditions Measles Mumps Rubella Varicella
Interventions V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks
Updated 8 times since 2017 Last updated: Nov 13, 2019 Started: Sep 26, 2002 Primary completion: Jun 9, 2003 Completion: Jun 9, 2003

This PHASE3 trial investigates Measles and Mumps and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 8 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jun 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jun 2022 [monthly]

    Completed PHASE3

  5. Dec 2019 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 3 earlier versions

  1. Jun 2018 — Dec 2019 [monthly]

    Completed PHASE3

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.